Cargando…

TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?

Detalles Bibliográficos
Autores principales:	Kim, Michael D., Salathe, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159432/ https://www.ncbi.nlm.nih.gov/pubmed/31913655 http://dx.doi.org/10.1164/rccm.201912-2519ED

Ejemplares similares

TMEM16A in Cystic Fibrosis: Activating or Inhibiting?
por: Kunzelmann, Karl, et al.
Publicado: (2019)

TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis
por: Danahay, Henry L., et al.
Publicado: (2020)

TMEM16A: An Alternative Approach to Restoring Airway Anion Secretion in Cystic Fibrosis?
por: Danahay, Henry, et al.
Publicado: (2020)

TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis
por: Mitri, Christie, et al.
Publicado: (2021)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

TMEM16A and TMEM16B Modulate Pheromone-Evoked Action Potential Firing in Mouse Vomeronasal Sensory Neurons
por: Hernandez-Clavijo, Andres, et al.
Publicado: (2021)

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia
por: Veit, Guido, et al.
Publicado: (2012)

Losartan ameliorates TGF-β1–induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies
por: Kim, Michael D., et al.
Publicado: (2022)

TMEM16A Potentiation: Possible Drawbacks
por: Olschewski, Andrea, et al.
Publicado: (2020)

The Need for Precision Therapies as Determined by Genetic Signature for Cystic Fibrosis
por: Zahir, Farah R.
Publicado: (2021)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

Development of the Olfactory Epithelium and Nasal Glands in TMEM16A(-/-) and TMEM16A(+/+) Mice
por: Maurya, Devendra Kumar, et al.
Publicado: (2015)

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021)

Niclosamide potentiates TMEM16A and induces vasoconstriction
por: Liang, Pengfei, et al.
Publicado: (2023)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Dynamic regulation of airway surface liquid pH by TMEM16A and SLC26A4 in cystic fibrosis nasal epithelia with rare mutations
por: Delpiano, Livia, et al.
Publicado: (2023)

The role of TMEM16A (ANO1) and TMEM16F (ANO6) in cell migration
por: Jacobsen, K. S., et al.
Publicado: (2013)

Newborn Screening for Cystic Fibrosis: Over the Hump, Still Need to Fine-Tune It
por: Castellani, Carlo
Publicado: (2020)

Modulator treatment for people with cystic fibrosis: moving in the right direction
por: Elborn, J. Stuart
Publicado: (2020)

Towards a new definition of non-cystic fibrosis bronchiectasis
por: Martinez-Garcia, Miguel Ángel, et al.
Publicado: (2022)

Divalent Cation Modulation of Ion Permeation in TMEM16 Proteins
por: Nguyen, Dung M., et al.
Publicado: (2021)

The Anion Channel TMEM16a/Ano1 Modulates CFTR Activity, but Does Not Function as an Apical Anion Channel in Colonic Epithelium from Cystic Fibrosis Patients and Healthy Individuals
por: Salari, Azam, et al.
Publicado: (2023)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

CFTR Modulators to the Rescue of Individuals with Cystic Fibrosis and Advanced Lung Disease
por: Myerburg, Mike, et al.
Publicado: (2021)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

Is Gastroparesis Found More Frequently in Patients with Cystic Fibrosis? A Systematic Review
por: Corral, Juan E., et al.
Publicado: (2016)

Contrasting effects of phosphatidylinositol 4,5‐bisphosphate on cloned TMEM16A and TMEM16B channels
por: Ta, Chau M, et al.
Publicado: (2017)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cellular functions of TMEM16/anoctamin
por: Oh, Uhtaek, et al.
Publicado: (2016)

TMEM16A as a potential treatment target for head and neck cancer
por: Okuyama, Kohei, et al.
Publicado: (2022)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
por: Ben-Meir, Elad, et al.
Publicado: (2022)

Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks
por: Danahay, Henry L., et al.
Publicado: (2020)

Positive modulation of the TMEM16B mediated currents by TRPV4 antagonist
por: Hernandez, Adan, et al.
Publicado: (2021)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_82umqhd6s2i7ria6ltbq78v6rd